Christine Chiou
Senior Vice President, Investor Relations
Replay available
Zai Lab Limited (NASDAQ: ZLAB) Q2 2026 earnings conference call, held 2026-08-06. Replay captured from the company's public earnings webcast.

Senior Vice President, Investor Relations
Founder, CEO, and Chairperson
President and Head of Global Research and Development
Chief Financial Officer
Chief Business Officer
Analyst, Cantor
Analyst, Levering Partners
Analyst, Goldman Sachs
Analyst, JPMorgan
Hello ladies and gentlemen, thank you for standing by and welcome to Xilabs second quarter 2026 financial results conference call. At this time all participants are in listen only mode. Later we'll conduct a question and answer session and instructions will follow at a time. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to Christine Chiou Senior Vice President of the Investor Relations. Please go ahead, ma'am. Thank you, operator. Hello and welcome, everyone. Today's earnings call will be led by Dr. Samantha Du, Scilabs founder, CEO, and chairperson. She will be joined by Dr. Rafael Amado, President and Head of Global Research and Development, and Dr. Yajing Chen, Chief Financial Officer. Dr. Shan He, our Chief Business Officer, and Dr. Yuzhe Wang, Our operating partner will also be available to answer questions during the Q&A portion of the call. As a reminder, during today's call, we will be making certain forward-looking statements based on our current expectations. These statements are subject to numerous risks and uncertainties that may cause actual results to differ materially from what we expect due to a variety of factors, including those discussed in our SDC filings. We will also refer to adjusted loss from operations, which is a non-GAAP financial measure. please refer to our earnings release furnished with the SEC on August 6th, 2026 for additional information on this non-GAAP financial measure. At this time, it is my pleasure to turn the call over to Dr. Samantha Du. Thanks, Christine. Good morning and good evening, everyone. Thank you for joining us today. That lab has reached the important inflection point in its evolution from original business into a global biopharmaceutical company. We built this company ...